Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.

Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner A, Armstrong TD, Jaffee EM.

Int J Cancer. 2011 Aug 1;129(3):636-47. doi: 10.1002/ijc.25693. Epub 2010 Nov 12.

3.

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT.

J Immunol. 2006 Jan 15;176(2):974-83.

4.
5.

Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM.

J Immunol. 2011 Apr 1;186(7):3847-57. doi: 10.4049/jimmunol.1000361. Epub 2011 Feb 23.

7.
8.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.

10.

Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer.

Peng LS, Zhuang Y, Shi Y, Zhao YL, Wang TT, Chen N, Cheng P, Liu T, Liu XF, Zhang JY, Zuo QF, Mao XH, Guo G, Lu DS, Yu PW, Zou QM.

Cancer Immunol Immunother. 2012 Nov;61(11):2183-92. doi: 10.1007/s00262-012-1277-6. Epub 2012 May 22.

PMID:
22729557
11.

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM.

J Exp Med. 2005 May 16;201(10):1591-602. Epub 2005 May 9.

12.

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.

Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN.

Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16.

13.

B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.

Wang X, Wang T, Xu M, Xiao L, Luo Y, Huang W, Zhang Y, Geng W.

Hum Immunol. 2014 Dec;75(12):1203-9. doi: 10.1016/j.humimm.2014.10.002. Epub 2014 Oct 13.

PMID:
25446402
14.
15.

Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.

Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD.

PLoS One. 2012;7(2):e31962. doi: 10.1371/journal.pone.0031962. Epub 2012 Feb 16.

17.

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM.

J Clin Invest. 2008 May;118(5):1700-11. doi: 10.1172/JCI34333.

18.
19.

Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.

Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA.

Hum Pathol. 2013 Oct;44(10):2055-63. doi: 10.1016/j.humpath.2013.03.010. Epub 2013 May 21.

20.

T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.

Quatromoni JG, Morris LF, Donahue TR, Wang Y, McBride W, Chatila T, Economou JS.

J Hematol Oncol. 2011 Nov 23;4:48. doi: 10.1186/1756-8722-4-48.

Supplemental Content

Support Center